Literature DB >> 10330062

Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis.

R J Schmidt1, S Yokota, T S Tracy, M I Sorkin, C Baylis.   

Abstract

To test the hypothesis that nitric oxide (NO) deficiency occurs in end-stage renal disease (ESRD), NO oxidation products (NO2 + NO3 = NOx) and cGMP were measured in blood, urine, and dialysate effluent of peritoneal dialysis (PD) patients and compared with blood and urine of healthy subjects. All subjects were on a controlled low-nitrate diet (approximately 330 micromol/day). NOx and cGMP outputs were significantly reduced in PD patients (334 +/- 50 micromol/24 h and 55 +/- 13 nmol/24 h, respectively) vs. controls (823 +/- 101 micromol/24 h and 149 +/- 46 nmol/24 h). Plasma arginine was borderline low, plasma citrulline was elevated and plasma levels of the endogenous NO synthase inhibitor asymmetric dimethylarginine were approximately five time higher in PD patients (2.2 +/- 0.3 microM) vs. controls (0.4 +/- 0.1 microM). Although blood pressure (BP) was not different between groups at the time of study, 10 of 11 PD patients were on medication for hypertension. These studies demonstrate that total NO production is low in ESRD, and with appropriate caution, we conclude that this NO deficiency may contribute to the increased BP that occurs in ESRD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10330062      PMCID: PMC2793680          DOI: 10.1152/ajprenal.1999.276.5.F794

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  17 in total

Review 1.  Regulation of enzymes of urea and arginine synthesis.

Authors:  S M Morris
Journal:  Annu Rev Nutr       Date:  1992       Impact factor: 11.848

Review 2.  Nitric oxide: physiology, pathophysiology, and pharmacology.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

3.  Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production.

Authors:  I Ashab; G Peer; M Blum; Y Wollman; T Chernihovsky; A Hassner; D Schwartz; S Cabili; D Silverberg; A Iaina
Journal:  Kidney Int       Date:  1995-06       Impact factor: 10.612

4.  Deficiency of endogenous arginine synthesis provokes hypertension by exhausting substrate arginine for nitric oxide synthesis.

Authors:  Y Wakabayashi; E Yamada; T Yoshida; H Takahashi
Journal:  Biochem Biophys Res Commun       Date:  1994-12-15       Impact factor: 3.575

Review 5.  Role of arginine in health and in renal disease.

Authors:  A A Reyes; I E Karl; S Klahr
Journal:  Am J Physiol       Date:  1994-09

Review 6.  Nitric oxide and blood pressure: effects of nitric oxide deficiency.

Authors:  C Baylis; P Vallance
Journal:  Curr Opin Nephrol Hypertens       Date:  1996-01       Impact factor: 2.894

7.  Cardiovascular complications in renal failure.

Authors:  S G Rostand; J D Brunzell; R O Cannon; R G Victor
Journal:  J Am Soc Nephrol       Date:  1991-12       Impact factor: 10.121

8.  Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure.

Authors:  P Vallance; A Leone; A Calver; J Collier; S Moncada
Journal:  Lancet       Date:  1992-03-07       Impact factor: 79.321

9.  Acute changes in urinary excretion of nitrite + nitrate do not necessarily predict renal vascular NO production.

Authors:  T Sütö; G Losonczy; C Qiu; C Hill; L Samsell; J Ruby; N Charon; R Venuto; C Baylis
Journal:  Kidney Int       Date:  1995-10       Impact factor: 10.612

Review 10.  Glomerular actions of nitric oxide.

Authors:  L Raij; C Baylis
Journal:  Kidney Int       Date:  1995-07       Impact factor: 10.612

View more
  28 in total

1.  Uremic levels of urea inhibit L-arginine transport in cultured endothelial cells.

Authors:  S Xiao; L Wagner; J Mahaney; C Baylis
Journal:  Am J Physiol Renal Physiol       Date:  2001-06

2.  Protection against puromycin aminonucleoside-induced chronic renal disease in the Wistar-Furth rat.

Authors:  Aaron Erdely; Gary Freshour; Cheryl Smith; Kevin Engels; Jean L Olson; Chris Baylis
Journal:  Am J Physiol Renal Physiol       Date:  2004-03-23

3.  Salt-induced renal injury in spontaneously hypertensive rats: effects of nebivolol.

Authors:  Jasmina Varagic; Sarfaraz Ahmad; K Bridget Brosnihan; Javad Habibi; Roger D Tilmon; James R Sowers; Carlos M Ferrario
Journal:  Am J Nephrol       Date:  2010-11-02       Impact factor: 3.754

4.  eNOS Glu298Asp Polymorphism and Endothelial Dysfunction in Patients with and without End-stage Renal Disease.

Authors:  Nevin İlhan; Kadir Ateş; Necip İlhan; Dilara Kaman; Hüseyin Çeliker
Journal:  Balkan Med J       Date:  2016-03-01       Impact factor: 2.021

Review 5.  Arginine, arginine analogs and nitric oxide production in chronic kidney disease.

Authors:  Chris Baylis
Journal:  Nat Clin Pract Nephrol       Date:  2006-04

6.  Indices of activity of the nitric oxide system in hemodialysis patients.

Authors:  R J Schmidt; J Domico; L S Samsell; S Yokota; T S Tracy; M I Sorkin; K Engels; C Baylis
Journal:  Am J Kidney Dis       Date:  1999-08       Impact factor: 8.860

7.  Circulating endothelial nitric oxide synthase inhibitory factor in some patients with chronic renal disease.

Authors:  S Xiao; L Wagner; R J Schmidt; C Baylis
Journal:  Kidney Int       Date:  2001-04       Impact factor: 10.612

8.  Protection of wistar furth rats from chronic renal disease is associated with maintained renal nitric oxide synthase.

Authors:  Aaron Erdely; Laszlo Wagner; Veronica Muller; Attila Szabo; Chris Baylis
Journal:  J Am Soc Nephrol       Date:  2003-10       Impact factor: 10.121

9.  Sex differences in response to cyclosporine immunosuppression in experimental kidney transplantation.

Authors:  Veronika Muller; Attila J Szabo; Aaron Erdely; You-Lin Tain; Chris Baylis
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-12-07       Impact factor: 2.557

Review 10.  Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review.

Authors:  Johannes Jacobi; Philip S Tsao
Journal:  Am J Nephrol       Date:  2007-10-24       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.